Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...

Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for ...

BTK inhibitors (BTKi) in mantle cell lymphoma (MCL) are examined by Tycel J. Phillips, MD, particularly as potential first-line therapy.

A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations. Today we are ...

New research led by scientists at VCU Massey Comprehensive Cancer Center suggests that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor ...

It’s called ibrutinib, and it’s a potential breakthrough in treating chronic lymphocytic leukemia (CLL) that could leave patients with fewer side effects than chemotherapy. In research published in ...

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in ...